The Rise of Off-Brand Ozempic
GLP-1 drugs like Ozempic and Wegovy are in high demand and short supply. The internet makes it easy for you to have a compounding pharmacy whip you up a batch—but should you?Guest: Kate Knibbs, senior...
18 Aug 202419min
Elon Musk’s Bully Pulpit
Since Elon Musk took over Twitter - now X - in 2022, he’s increasingly used it to push his conservative views. A suit against a non-profit brand safety group of advertisers and an exclusive interview ...
16 Aug 202421min
Would You Die For MrBeast?
MrBeast is known for videos that blend stunts and philanthropy, but his new team-up with Amazon and MGM is bringing some of his less savory aspects to light.Guest: Madison Malone Kircher, reporter cov...
15 Aug 202423min
Trump Seems Lost. But Can He Lose?
Donald Trump’s presidential opponent has changed—can he? Should he?Guest: Tom Nichols, staff writer at the Atlantic and professor emeritus at the U.S. Naval College. Want more What Next? Subscribe to ...
14 Aug 202425min
How Boeing Stranded Two Astronauts
It was supposed to be the triumphant rollout of Boeing’s new, reusable space taxi. Now NASA’s trying to find some other way to get two astronauts home.Guest: Joey Roulette, space reporter at Reuters.W...
13 Aug 202421min
AIPAC Vs. The Squad
A Republican-backed organization is spending millions to unseat progressive Democrats—and it’s succeeding.Guest: Alexander Sammon, Slate politics writer.Want more What Next? Subscribe to Slate Plus to...
12 Aug 202420min
Tesla’s Out of Juice. But Are EVs?
The hype has slowed but electric vehicles aren’t going away—once the infrastructure is in place, they’ll go everywhere.Guests: Nitish Pahwa, associate writer for business and tech at Slate.Paula Gardn...
11 Aug 202423min
Google’s a Monopoly. What About The Rest?
Should the other Silicon Valley giants be worried following the Department of Justice’s decisive win against Google? Guest: Leah Nylen, antitrust reporter at BloombergWant more What Next TBD? Subscrib...
9 Aug 202420min
